Company intelligence / Profile preview
Acanthas Pharma, Inc.
Montréal, Quebec, Canadaacanthuspharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company's lead drug candidate STAR-101 was in clinical development but has been discontinued. A Phase 1 clinical trial (NCT04081597) for evaluating the safety, tolerability, and pharmacokinetic properties of STAR-101 was withdrawn[4].
- Therapeutic areas
- Oncology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
TVM Capital Life Science
Beyond the preview
Go deeper on Acanthas Pharma, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Acanthas Pharma, Inc..